"Working at Genentech provides an unparalleled opportunity to do amazing science while working to improve and extend patient’s lives."
I arrived at Genentech in 2010 to join a nascent Process Chemistry team within the Small Molecule Pharmaceutical Sciences function. Though the group was initially tasked with delivering traditional pharmaceuticals focused on oncology, we have grown to impact a larger swath of the pipeline. This has included collaborative efforts to assemble new molecular constructs, explore extended release formulations, etc., in therapeutic areas such as immunologic, ocular, respiratory, and infectious diseases.
What I like about doing science at Genentech is that we intrepidly pursue medicines to treat unmet needs. Though it may take great effort, we are dedicated to finding the best treatment and consider what patients will require once our products reach them. Purposefully, the organization provides support to bring this vision to reality and encourages pushing the limits of chemistry to achieve our goals. We are also charged with publishing our findings so that the scientific community can benefit.
Chemistry. 2018 Feb 26;24(12):2837-2840.
As a scientist at Genentech, I lead teams to deliver robust CMC attributes supporting pipeline compounds in development. We implement phase-appropriate Process Chemistry to supply the clinic and beyond. I have been involved with advancing projects ranging from small molecules to antibody conjugates to novel formulations of unusual modalities.
My independent research focuses exploring Green Chemistry tools and techniques to benefit the greater scientific community, and facilitate more sustainable research and development in the pharma industry. Publications from my team include work in C-H functionalization, base metal catalysis, and utilizing O2 as a terminal oxidant in transition metal catalysis.